Doing some rough calculations:
- USA GvHD market is expected to be 8x Japan's
- treatment cost is expected to be 1.25-2x cost of Temcell
- latest Japan revenue from Temcell is $6.6m usd ($9m aud)
- Projected annual USA revenue at 2020 levels therefore = $90m-$144m aud
-Assuming a p/e ratio of 41.8 (equivalent of csl) value of Rynocil approval gives a sp of: $6.43-$10.29 or a valuation of MSB of $3.762b-$6.019b
- Note that this excludes milestone payments, future Rynocil and Temcell earnings growth and any potential earning from future unapproved products including Covid-19 ARDS.
- Forums
- ASX - By Stock
- Pick the Closing Price after FDA approval on that day
Doing some rough calculations:- USA GvHD market is expected to...
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 97.0¢ | $2.821M | 2.832M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20688 | 97.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 35000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20688 | 0.975 |
6 | 137742 | 0.970 |
6 | 111862 | 0.965 |
5 | 79094 | 0.960 |
1 | 5200 | 0.955 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 35000 | 3 |
0.995 | 69662 | 5 |
1.000 | 33108 | 4 |
1.005 | 20000 | 1 |
1.010 | 73320 | 2 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online